Evaluation of ICP-B381 in Patients With Advanced Solid Tumors
An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics, and Efficacy of ICP-B381 in Participants With Advanced Solid Tumors
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B381 in the trial participants of advanced solid tumors
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Jingnan Yang
- Telefonnummer: 010-66609990
- E-Mail: CO-Clinicaltrial@innocarepharma.com
Studienorte
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200032
- Rekrutierung
- Fudan University Shanghai Cancer Center
-
Kontakt:
- DingWei Ye, M.D.
- Telefonnummer: 021-64175590*81807
- E-Mail: dwyeli@163.com
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participants must be at least 18 years old.
- Participants thoroughly understand study procedures, and voluntarily sign the written ICF
- Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.
- Expected survival time ≥3 months.
- Histopathologically confirmed metastatic castration-resistant prostate cancer (mCRPC) & Other advanced solid tumor
- Agree to provide FFPE slides from archived tumor tissues collected within the past 2 years or fresh tumor biopsies (for archived samples, more recently collected specimens are preferred
- The organ function level must meet the prescribed standards
- All toxicities derived from previous anti-neoplasm treatments must have been resolved to Grade ≤1 (per CTCAE V6.0)
- Effective contraceptive measures should be taken from the date of signing the informed consent form until at least 6 months after the use of the last dose of the study drug
- Female participant of childbearing potential must have a negative blood pregnancy test at the screening visit
- Female participants must not breastfeed or plan pregnancy during the study and for at least 6 months after the last dose.
- Participants can communicate well with the Investigator and can complete the study according to the study protocol
Exclusion Criteria:
- Other active malignant tumors occurred within 3 years before the first administration of the study drug
- Has previously received or is currently receiving the same type of drug or related treatment as stipulated in the protocol
- Has a previous medical history and adverse life history as specified in the protocol, or has a disease as specified in the protocol
- Has received cytotoxic chemotherapy, radical radiotherapy, molecular targeted therapy, immunotherapy, anti-tumor vaccine therapy, cytokine therapy, or other investigational anti-cancer drugs with an elution time not meeting the protocol requirements
- Had active bleeding within 2 months before screening or had clinically significant or significant bleeding tendency, or was experiencing bleeding symptoms due to taking anticoagulant drugs or other medical interventions
- Had major surgery within 28 days before the first administration or minor surgery within 2 weeks before the first administration
- Has received systemic immunosuppressive drugs as stipulated in the protocol for 14 days before the first administration
- Has a history of severe allergic reactions to the active ingredient, non-active ingredients in the drug, or antibody-based drugs
- Had the first administration within 2 weeks before or is planned to use drugs or foods with strong inhibitory or inducing effects on cytochrome P450 CYP3A before the study
- Has any mental or cognitive disorders that may limit their understanding, execution of the informed consent form, and compliance with the study
- Situations that the investigator deems unsuitable for participating in this study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: ICP-B381
|
ICP-B381 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first). |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
The type, severity (assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0 [NCI-CTCAE V6.0]), relationship to the investigational product, and incidence rate of adverse event (AE) and serious advers
Zeitfenster: 2 years
|
2 years
|
|
The type, severity (assessed according to NCI-CTCAE V6.0), and incidence rate of dose limiting toxicity (DLT)
Zeitfenster: 2 years
|
2 years
|
|
Single-agent Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD)
Zeitfenster: 2 years
|
2 years
|
|
Participants with prostate cancer: Prostate-specific antigen (PSA50) response rate
Zeitfenster: 2 years
|
2 years
|
|
Participants with other tumor types: Investigator-assessed Objective response rate (ORR)
Zeitfenster: 2 years
|
2 years
|
|
The optimal dosing regimen for the subsequent study of ICP-B381
Zeitfenster: 2 years
|
2 years
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Gesamtüberleben (OS)
Zeitfenster: 2 Jahre
|
2 Jahre
|
|
Dauer des Ansprechens (DOR)
Zeitfenster: 2 Jahre
|
2 Jahre
|
|
Objektive Ansprechrate (ORR)
Zeitfenster: Zwei Jahre
|
Zwei Jahre
|
|
Maximale Konzentration (Cmax)
Zeitfenster: Zwei Jahre
|
Zwei Jahre
|
|
Krankheitskontrollrate (DCR)
Zeitfenster: 2 Jahre
|
2 Jahre
|
|
Time to Maximum Plasma Concentration (Tmax)
Zeitfenster: 2 years
|
2 years
|
|
Half-life (T1/2)
Zeitfenster: 2 years
|
2 years
|
|
Area Under the Serum or Plasma Concentration-Time Curve (AUC0-∞ and AUC0-t)
Zeitfenster: 2 years
|
2 years
|
|
Apparent Clearance Rate (CL/F)
Zeitfenster: 2 years
|
2 years
|
|
Terminal Apparent Volume of Distribution (Vz/F)
Zeitfenster: 2 years
|
2 years
|
|
Steady-state Pharmacokinetic Parameters
Zeitfenster: 2 years
|
2 years
|
|
Participants with prostate cancer: radiographic progression-free survival (rPFS) evaluated by the Investigator according to RECIST V1.1 criteria (for soft tissue lesions) and PCWG3 criteria (for bone lesions)
Zeitfenster: 2 years
|
2 years
|
|
Participants with prostate cancer: changes in serum PSA levels compared to baseline during the study: PSA50 response rate
Zeitfenster: 2 years
|
2 years
|
|
Participants with prostate cancer: PSA90 response rate
Zeitfenster: 2 years
|
2 years
|
|
Participants with prostate cancer:12-week PSA response rate
Zeitfenster: 2 years
|
2 years
|
|
Participants with prostate cancer: time to PSA progression (TTPP)
Zeitfenster: 2 years
|
2 years
|
|
Time to First Subsequent Therapy (TFST)
Zeitfenster: 2 years
|
2 years
|
|
Participants with prostate cancer: incidence rate of symptomatic skeletal event (SSE)
Zeitfenster: 2 years
|
2 years
|
|
Participants with prostate cancer: time to first symptomatic skeletal event (TTSSE)
Zeitfenster: 2 years
|
2 years
|
|
Incidence rate of anti-drug antibody (ADA) against ICP-B381
Zeitfenster: 2 years
|
2 years
|
|
Types, severity (assessed according to NCI-CTCAE V6.0), relationship with the investigational product, and incidence rate of AE and SAE
Zeitfenster: 2 years
|
2 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- ICP-CL-01901
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .